Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

199 ta ish

Ish: Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

  1. Neoantigens: promising targets for cancer therapy

    Na Xie, Guobo Shen, Wei Gao +3

    Sharh maqolaOchiq kirish20236 iqtibos
    ABI

  2. CAR-T cell therapy: current limitations and potential strategies

    Robert C. Sterner, Rosalie M. Sterner

    Sharh maqolaOchiq kirish20215 iqtibos
    ABI

  3. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

    Xinyi Xiao, Shengkang Huang, Sifei Chen +4

    Sharh maqolaOchiq kirish20215 iqtibos
    ABI

  4. Regulatory mechanisms of PD-1/PD-L1 in cancers

    Xin Lin, Kuan Kang, Pan Chen +5

    MaqolaOchiq kirish20245 iqtibos
    ABI

  5. Exploring treatment options in cancer: tumor treatment strategies

    Beilei Liu, Hongyu Zhou, Licheng Tan +2

    Sharh maqolaOchiq kirish20245 iqtibos
    ABI

  6. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

    Lei Peng, Giacomo Sferruzza, Luojia Yang +2

    Sharh maqolaOchiq kirish20245 iqtibos
    ABI

  7. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells

    Miyuki Tanaka, Haruko Tashiro, Bilal Omer +9

    MaqolaOchiq kirish20174 iqtibos
    ABI

  8. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

    Levi J. Rupp, Kathrin Schumann, Kole T. Roybal +4

    MaqolaOchiq kirish20174 iqtibos
    ABI

  9. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

    Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

    MaqolaOchiq kirish20174 iqtibos
    ABI

  10. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

    Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis +6

    MaqolaOchiq kirish20174 iqtibos
    ABI

  11. CAR-T Cell Performance: How to Improve Their Persistence?

    Gina López-Cantillo, Claudia Urueña, Bernardo Camacho +1

    Sharh maqolaOchiq kirish20224 iqtibos
    ABI

  12. Engineering CAR-T Cells for Next-Generation Cancer Therapy

    Mihe Hong, Justin Clubb, Yvonne Y. Chen

    Sharh maqolaOchiq kirish20203 iqtibos
    ABI

  13. Bispecific T‐cell engagers for cancer immunotherapy

    Amelia M. Huehls, Tiffany A. Coupet, Charles L. Sentman

    Sharh maqolaOchiq kirish20143 iqtibos
    ABI

  14. CRISPR-engineered T cells in patients with refractory cancer

    Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38

    MaqolaOchiq kirish20203 iqtibos
    ABI

  15. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

    Andriy Marusyk, Michalina Janiszewska, Kornélia Polyák

    Sharh maqolaOchiq kirish20203 iqtibos
    ABI

  16. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

    Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12

    MaqolaOchiq kirish20213 iqtibos
    ABI

  17. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

    Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27

    MaqolaOchiq kirish20213 iqtibos
    ABI

  18. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

    Zhenguang Wang, Na Li, Kaichao Feng +14

    MaqolaOchiq kirish20213 iqtibos
    ABI

  19. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

    Changsong Qi, Jifang Gong, Jian Li +23

    MaqolaOchiq kirish20223 iqtibos
    ABI

  20. Long-term outcomes following CAR T cell therapy: what we know so far

    Kathryn M. Cappell, James N. Kochenderfer

    Sharh maqolaOchiq kirish20233 iqtibos
    ABI

  21. Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases

    Agata Kieliszek, Daniel Mobilio, Deepak Upreti +10

    Maqola20233 iqtibos
    ABI

  22. In vivo CAR T cell generation to treat cancer and autoimmune disease

    Theresa Hunter, Yanjie Bao, Yan Zhang +37

    Maqola20253 iqtibos
    ABI

  23. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

    Christine E. Brown, Behnam Badie, Michael E. Barish +14

    MaqolaOchiq kirish20152 iqtibos
    ABI

  24. Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition

    Serena Perna, Daria Pagliara, Aruna Mahendravada +4

    MaqolaOchiq kirish20132 iqtibos
    ABI

  25. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

    Omkar U. Kawalekar, Roddy S. O’Connor, Joseph A. Fraietta +11

    MaqolaOchiq kirish20162 iqtibos
    ABI